Precigen, Inc. (NASDAQ:PGEN - Get Free Report) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.52 and traded as low as $1.47. Precigen shares last traded at $1.52, with a volume of 9,207,486 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the stock. JMP Securities reissued a "market outperform" rating and issued a $6.00 price target on shares of Precigen in a research report on Thursday, June 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. Finally, Wall Street Zen raised shares of Precigen from a "sell" rating to a "hold" rating in a report on Saturday, July 12th.
Read Our Latest Analysis on PGEN
Precigen Trading Down 16.9%
The firm has a market capitalization of $448.67 million, a P/E ratio of -2.71 and a beta of 1.78. The company's fifty day moving average is $1.51 and its 200-day moving average is $1.52.
Precigen (NASDAQ:PGEN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative net margin of 3,728.87% and a negative return on equity of 279.20%. The business had revenue of $1.34 million during the quarter, compared to analysts' expectations of $0.50 million. On average, equities research analysts anticipate that Precigen, Inc. will post -0.32 EPS for the current year.
Hedge Funds Weigh In On Precigen
A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in shares of Precigen in the fourth quarter valued at about $27,000. Envestnet Asset Management Inc. lifted its holdings in shares of Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 5,915 shares during the last quarter. Boothbay Fund Management LLC bought a new position in shares of Precigen in the fourth quarter worth about $35,000. Apella Capital LLC bought a new position in shares of Precigen in the first quarter worth about $40,000. Finally, RPO LLC bought a new position in shares of Precigen in the fourth quarter worth about $47,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
